Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 3

1(16.7%)

Phase 4

1(16.7%)

6Total

N/A(4)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05510804Not ApplicableUnknown

Efficacy of an App-based CBT Featuring Virtual Reality for Anxiety Disorders

Role: collaborator

NCT01033708Not ApplicableUnknown

A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder

Role: lead

NCT00993876Not ApplicableCompleted

Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment

Role: lead

NCT00484757Not ApplicableUnknown

Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition

Role: lead

NCT00291239Phase 4Unknown

Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression

Role: lead

NCT00300404Phase 3Completed

Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression

Role: lead

All 6 trials loaded